key: cord-1026500-bdkgdy2p
authors: Merli, Marco; Perricone, Giovanni; Lauterio, Andrea; Prosperi, Manlio; Travi, Giovanna; Roselli, Elena; Petrò, Laura; De Carlis, Luciano; Belli, Luca; Puoti, Massimo
title: Reply to “Coronaviruses and immunosuppressed patients. The facts during the third epidemic”
date: 2020-05-31
journal: Liver Transpl
DOI: 10.1002/lt.25806
sha: e7c58fb19e068ef599606c208484ba9fbee4e80e
doc_id: 1026500
cord_uid: bdkgdy2p

We read with interest the letter by D’Antiga evaluating the early experience with Coronavirus‐19 disease (COVID‐19) in liver transplant (LT) recipients in Bergamo and suggesting the absence of correlation between immunosuppression and severity of disease. We report two cases of early liver transplant recipients infected by SARS‐CoV‐2 with only mild clinical manifestations. On the contrary, long‐term recipients with comorbities showed a more aggressive course and worse prognosis. Considering the emerging evidence of the contribution of immune activation in the severity of the COVID‐19, immunosuppression may in part prevent a more aggressive course of the disease.

This article is protected by copyright. All rights reserved transplants/year performed in the last 5 years) and requiring hospital admission: 2/5 needed noninvasive ventilation, 3/5 died due to respiratory failure (n=2) or septic shock in neutropenia following chemotherapy for lymphoma (n=1). Among them 3/5 were affected by diabetes mellitus, 4/5 by arterial hypertension and 2/5 by advanced cancer, supporting previous report 2 on the role of co-morbidities in LT recipients with COVID-19. As recently observed 1 , severe immunosuppression -as in the early post-transplant period -does not appear to negatively affect the outcome and calcineurin inhibitors may also partly suppress the innate immune response 4 ,

This article is protected by copyright. All rights reserved which appears to play a relevant role in the pathophysiology of severe disease in SARS-CoV-2 infection. Nonetheless, since other immunomodulating therapies are emerging in the treatment of COVID-19 (ie. tocilizumab, high-dose steroid), caution is warranted to limit the risk of superimposing bacterial and fungal infections, especially in critically ill patients. Moreover, prompt identification of cases and their management in COVID-dedicated areas by a multidisciplinary team can limit the nosocomial spreading of the infection without negatively affecting regular care to hospitalised patients.

Coronaviruses and immunosuppressed patients. The facts during the third epidemic

COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Effects of Antirejection Drugs on Innate Immune Cells After Kidney Transplantation

Accepted Article